ArticleThe American journal of pathology2009
Decreased TIP30 expression promotes tumor metastasis in lung cancer.
Article in The American journal of pathology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Tat-Interacting Protein 30 (TIP30) Expression Serves as a New Biomarker for Tumor Prognosis: A Systematic Review and Meta-Analysis.PloS one · 2016Pooled it
- HTATIP2 regulates arteriogenic activity in monocytes from patients with limb ischemia.JCI insight · 2023Article
- Integration and deconvolution methodology deciphering prognosis-related signatures in lung adenocarcinoma.Journal of cancer research and clinical oncology · 2023Article
- Genome-wide association study of the age of onset of type 1 diabetes reveals HTATIP2 as a novel T cell regulator.Frontiers in immunology · 2023Article
- TIP30 overcomes gefitinib resistance by regulating cytoplasmic and nuclear EGFR signaling in non-small-cell lung cancer.Cancer science · 2021Article
- Absence of HTATIP2 Expression in A549 Lung Adenocarcinoma Cells Promotes Tumor Plasticity in Response to Hypoxic Stress.Cancers · 2020Article
- ALDH1A3 serves as a predictor for castration resistance in prostate cancer patients.BMC cancer · 2020Article
- TIP30 counteracts cardiac hypertrophy and failure by inhibiting translational elongation.EMBO molecular medicine · 2019Article
- Low TIP30 Protein Expression is Associated with a High Risk of Metastasis and Poor Prognosis for Non-Small-Cell Lung Cancer.Journal of clinical medicine · 2019Article
- Mechanism of membrane fusion: protein-protein interaction and beyond.International journal of physiology, pathophysiology and pharmacology · 2019Review
- Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis.Journal of acquired immune deficiency syndromes (1999) · 2018Article
- Human immunodeficiency virus Tat-TIP30 interaction promotes metastasis by enhancing the nuclear translocation of Snail in lung cancer cell lines.Cancer science · 2018Article
- TRIM36, a novel androgen-responsive gene, enhances anti-androgen efficacy against prostate cancer by inhibiting MAPK/ERK signaling pathways.Cell death & disease · 2018Article
- Reduction of Tat-interacting Protein 30 Expression Could be a Prognostic Marker in Bladder Urothelial Cancer.Chinese medical journal · 2018Article
- Positive expression of NR6A1/CT150 as a predictor of biochemical recurrence-free survival in prostate cancer patients.Oncotarget · 2017Article
- TIP30 regulates lipid metabolism in hepatocellular carcinoma by regulating SREBP1 through the Akt/mTOR signaling pathway.Oncogenesis · 2017Article
- A low serum Tat-interacting protein 30 level is a diagnostic and prognostic biomarker for hepatocellular carcinoma.Oncology letters · 2017Article
- Association of TIP30 expression and prognosis of hepatocellular carcinoma in patients with HBV infection.Cancer medicine · 2016Article
- Overexpression of TIP30 inhibits the growth and invasion of glioma cells.Molecular medicine reports · 2016Article
- Myo9b is a key player in SLIT/ROBO-mediated lung tumor suppression.The Journal of clinical investigation · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The HIV Tat-interacting protein (TIP30), also called CC3 or HTIP2, is encoded by Tip30, a putative tumor-suppressor gene located on human chromosome 11p15.1. In this study, we investigated the role of TIP30 in the progression and metastasis of lung cancer. TIP30 expression was analyzed in 206 paired lung cancers and adjacent non-tumor tissues, as well as in 70 matched lymph node metastases using a high-density tissue microarray. Results were compared with the clinicopathologic features of the patients from whom the tissues were taken. Low TIP30 expression levels were found in all 9 cases of small cell lung cancer and in 36.5% (72/197) of non-small cell lung cancer, which were correlated with lymph node metastasis in non-small cell lung cancer and with poor differentiation and advanced stage of tumor cells in squamous cell carcinoma. The immunostaining scores were significantly lower in the metastatic lesions than in the primary lesions. Down-regulation of TIP30 by a short hairpin RNA enhanced cell survival, migration, and invasion through Matrigel in vitro, and promoted lung metastasis and vascularization in nude mice. Further studies revealed that the down-regulation of TIP30 enhanced the expression of osteopontin, as well as matrix metalloproteinase-2 and vascular endothelial growth factor. Our results suggest that the down-regulation of TIP30 promotes metastatic progression of lung cancer, hence it could serve as a potential target for the development of lung cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.